Johnson & Johnson
JNJHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 9, 2026
Scan Results
Daily timeframeJohnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. With a market capitalization of $648.55B, it sits in mega-cap territory. It operates in two segments, Innovative Medicine and MedTech.
Market Cap
$648.55B
Beta
0.23
P/E (TTM)
31.26
P/E (Fwd)
21.87
EPS (TTM)
$8.61
EPS (Fwd)
$12.31
ROE
25.7%
ROA
8.6%
Cash
$20.76B
Total Debt
$49.04B
Free CF
$16.89B
52W Change
56.6%
Annual Financials
Cash vs Debt
Where JNJ stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, JNJ finished 13.84% above its 150-day moving average ($241.76) and 18.28% above its 200-day moving average ($232.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JNJ overbought or oversold?
At the September 3, 2026 close, JNJ's RSI(14) was 64.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $20.76B in cash, though total debt stands at $49.04B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $16.89B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 25.7% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $79.99B to $94.19B.
The relatively low beta of 0.23 suggests JNJ is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing JNJ.